Disposition of proguanil in Thai patients with uncomplicated falciparum malaria

American Journal of Tropical Medicine and Hygiene

Volumn 56, Issue 5, 1997, Pages 498-502

  Edstein, M D ^a   Looareesuwan, S ^b   Wilairatana, P ^b   Vanijanonta, S ^b   Kyle, D E ^c   Rieckmann, K H ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOGUANIL; PROGUANIL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESISTANCE; FEMALE; HUMAN; MALARIA FALCIPARUM; MALE; PLASMA CLEARANCE; THAILAND; TREATMENT FAILURE;

EID: 0030918825     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1997.56.498     Document Type: Article

References (24)

1. Adams ARD, Maegraith BG, King JD, Townshend RH, Davey TH, Havard RE, 1945. Studies on synthetic antimalarial drugs. XIII. Results of a preliminary investigation of the therapeutic action of 4888 (Paludrine) on acute attacks of benign tertian malaria. Ann Trop Med Parasitol 39: 225-231.
2. Fairley NH, 1946. Researches on paludrine (M4888) in malaria. An experimental investigation undertaken by the LHQ Medical Research Unit, Cairns, Australia. Trans R Soc Trop Med Hyg 40: 105-151.
3. Bradley DJ, Phillips-Howard PA, 1989. Prophylaxis against malaria for travellers from the United Kingdom. Br Med J 299: 1087-1089.
4. Watkins WM, Brandling-Bennett AD, Nevill CG, Carter JY, Bariga DA, Howells RE, Koech DK, 1988. Chlorproguanildapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans R Soc Trop Med Hyg 82: 398-403.
5. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ, 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54: 62-66.
6. Carrington HC, Crowther AF, Davey DG, Levi A, Rose FI, 1951. A metabolite of paludrine with high antimalarial activity. Nature 168: 1080.
7. Ward SA, Watkins WM, Mberu E, Saunders JE, Joech DK, Gilles HM, Howells RE, Breckenridge AM, 1989. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 27: 781-787.
8. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM, 1990. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30: 593-598.
9. Edstein MD, Shanks GD, Teja-Isavadharm P, Rieckmann KH, Webster HK, 1994. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 37: 67-70.
10. Brosen K, Skjelbo E, Flachs H, 1993. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36: 105-108.
11. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK, 1990. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 84: 492-495.
12. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ, 1987. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 24: 775-780.
13. Edstein MD, Veenendaal JR, Scott HV, Rieckmann KH, 1988. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy 34: 385-392.
14. Limsomwong N, Pang LW, Singharaj P, 1988. Malaria prophylaxis with proguanil in children living in a malaria-endemic area. Am J Trop Med Hyg 38: 231-236.
15. Shanks GD, Edstein MD, Chedester AL, Smith CD, Corcoran KD, Ngampochjana M, Hansukjariya P, Sattabongkot J, Webster HK, 1994. Proguanil plus sulfamethoxazole is not causally prophylactic in the Macaco mulatta-Plasmodium cynomolgi model. Am J Trop Med Hyg 50: 641-645.
16. Gibaldi M, Perrier D, 1982. Pharmacokinetics. Second edition. New York: Marcel Dekker.
17. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T, 1995. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 39: 297-303.
18. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T, 1982. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med 73: 564-572.
19. Karbwang J, Back DJ, Bunnag D, Breckenridge AM, 1988. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol 35: 677-680.
20. Karbwang J, Ward SA, Milton KA, Na-Bangchang K, Edwards G, 1991. Pharmacokinetics of halofantrine in healthy Thai volunteers. Br J Clin Pharmacol 32: 639-640.
21. Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-Ariya P, Karbwang J, 1994. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol 38: 278-281.
22. Harinasuta T, Bunnag D, 1988. Management of malaria with special reference to drug resistance. Jpn J Trop Med Hyg 16: 121-130.
23. Winstanley PA, Breckenridge AM, 1987. Currently important antimalarial drugs. Ann Trop Med Parasitol 81: 619-627.
24. Mberu EK, Wansor T, Sato H, Nishikawa Y, Watkins WM, 1995. Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Trans R Soc Trop Med Hyg 89: 658-659.